Randomized phase III trial comparing FOLFIRINOX (F: 5FU / leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial - Conroy, T; Desseigne, F; Ychou, M (J Clin Oncol, 2010)
(Suppl. Abstr. 4010)